Cboe UK CHF

Novartis AG (NOVNZ.XC)

94.22

+0.69

+(0.74%)

At close: 4:19:59 PM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for NOVNZ.XC

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Biotech Alert: Searches spiking for these stocks today

Novartis to strengthen renal disease portfolio with Regulus

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Novartis to acquire Regulus in deal for kidney disease drug

Novartis to Acquire Regulus in $1.7 Billion Deal

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance